Search

everythinglearnresearchcommunity

for

Search:↓

A user has been using a topical hair loss treatment with finasteride, minoxidil, and tretinoin for 4 years without satisfactory results and is considering switching to a different product due to concerns about effectiveness and company reliability. They are seeking others' experiences with Strut and alternative products before making a change.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

A user's experience with using stemoxydine, minoxidil, and finasteride together as a hair loss treatment stack.

Hair loss treatments discussed include alfatradiol, big 3, finasteride, RU58841, and stemoxydine. Alfatradiol is less effective but has fewer side effects, and mixing with stemoxydine may improve results.

A new stem cell method for culturing hair follicles is being developed as an alternative to Minoxidil, finasteride, and RU58841. There are concerns about its cost and accessibility despite plans for commercialization.

The user experienced significant hair regrowth using Trestolone, GHK-Cu, and Minoxidil. They avoided Finasteride due to concerns about side effects and noted that their approach reduced androgenic load, contributing to hair regrowth.

The user has been using finasteride, minoxidil, retinoid, and occasional microneedling for hair loss with good results. They recently added stemoxydine, which improved their hair further, and suggest trying it, especially in the EU where it's easily available.

Hair loss discussion includes treatments like hinoki tree oil and procyanidin b2. Experiences and effectiveness of these treatments are shared.

User experienced bad reaction to minoxidil and asks if anyone tried stemoxydine alone for hair loss. They consider trying stemoxydine with low dose topical finasteride after testing stemoxydine on a small area.

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation discusses using Stemoxydine, a hair growth stimulant considered weaker than Minoxidil, and questions whether applying it twice daily could improve results similar to twice-daily Minoxidil applications.

Stemoxydine may work synergistically with minoxidil and finasteride for hair growth, but its effectiveness is debated, with some users experiencing minimal results and concerns about cost. Users suggest sticking to proven treatments like minoxidil and finasteride, while considering stemoxydine as an additional option.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

A breakthrough in hair follicle cultivation using induced pluripotent stem cells (iPSCs) has been achieved, producing large hair follicles suitable for transplantation. Clinical trials for this hair multiplication technology are planned in partnership with Yinguan Biotechnology.

The user is using topical minoxidil and finasteride with good results and is considering adding stemoxydine 5% to their regimen. Another user suggests trying it if financially feasible, as results can vary.

Stem cell-related treatments and drugs like RCGD423 and WAY are being tested for hair growth. Clinics are conducting tests on patients who haven't had previous treatments.

The user is discussing their hair loss treatment stack, which includes CB-03-01, Fluridil, Alfatradiol, Cosmerna, microneedling, and Stemoxydine. They have seen some new hair growth but wish they could use finasteride.

Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Stemoxydine is discussed as a hair loss treatment with no reported side effects. The conversation explores its effectiveness and safety.

RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.

Hair loss discussion includes using stemoxydine mixed with finasteride tablets as a topical treatment. One user reports positive results with healthy hair and new growth in hairline.

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

The conversation discusses adding finasteride (Propecia) to a liquid containing stemoxydine for hair loss treatment. The user is inquiring about the effectiveness of this combination.

Hair loss discussion involves minoxidil, finasteride, and RU58841. Minoxidil non-responders may see results after adding stemoxydine due to increased enzyme presence.

AH-001 is a new topical treatment designed to degrade androgen receptors, targeting the root cause of androgenetic alopecia without the side effects of oral treatments like finasteride. It has shown a strong safety profile and good local tolerability in early trials.

The conversation is about the best vehicle for RU58841, comparing trichosol and Garnier/Vichy Stemoxydine, avoiding propylene glycol (PG) or ethanol due to previous scalp damage. The user is also seeking sources for these products in the EU.

The conversation is about making topical finasteride with stemoxydine, including questions on dosages, bulk preparation, and storage.

Hair loss discussion includes alfatradiol (Pantostin/Ell Cranell) as a potential treatment. Users share opinions on its effectiveness in their regimen.